Viridian Therapeutics, Inc.\DE VRDN
NASDAQ VRDN
$19.40 +0.41 (+2.16%)
At close: Oct 2, 2026 · 4:00 PM EDT

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities (2013 - 2026)

Updated

Viridian Therapeutics, Inc.\DE's Cash from Financing Activities was $325.12 million in Q2 2026, compared with $764,000 a year earlier.

Analysis

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities (2013 - 2026) Analysis & Trends

On a trailing twelve-month basis, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities was $748.24 million through Jun 30, 2026, up 157.6% year-over-year; for FY2025, it came in at $426.74 million, down 6.8% from FY2024.

  • Cash from Financing Activities shows a five-year compound annual growth rate of 33.3% (FY2020 to FY2025).
  • In earlier years, Cash from Financing Activities was $457.74 million in FY2024 (+102.8%), $225.67 million in FY2023 (-30.0%), $322.24 million in FY2022 (+157.2%) and $125.28 million in FY2021 (+23.7%).
  • Quarterly Cash from Financing Activities has moved between $108,000 (Q2 2024) and $405.91 million (Q4 2025) over five years.
  • Compared with a year earlier, Cash from Financing Activities was higher in 1 of the last five quarters, with growth averaging 60.8%.
  • The best year-over-year quarter for Cash from Financing Activities over five years was Q4 2023 (growth of 664.7%); the worst was Q4 2021 (a decline of 99.8%).
  • Per Business Quant data, VRDN's Cash from Financing Activities in the three quarters before Q2 2026 was $6.36 million (Q1 2026), $405.91 million (Q4 2025) and $10.86 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 8.43 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -8.78 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -5.05 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 1.76 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -2.02 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -47.00 Mn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -1.48 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 2.34 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -3.66 Bn
10 Viridian Therapeutics, Inc.\DE 2.20 Bn 2.20 Bn - 325.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 325.12 Mn
Mar 31, 2026 6.36 Mn
Dec 31, 2025 405.91 Mn
Sep 30, 2025 10.86 Mn
Jun 30, 2025 764,000.00
Mar 31, 2025 9.21 Mn
Dec 31, 2024 35.52 Mn
Sep 30, 2024 245.02 Mn
Jun 30, 2024 108,000.00
Mar 31, 2024 177.08 Mn
Dec 31, 2023 198.94 Mn
Sep 30, 2023 15.46 Mn
Jun 30, 2023 3.07 Mn
Mar 31, 2023 8.20 Mn
Dec 31, 2022 26.01 Mn
Sep 30, 2022 290.93 Mn
Jun 30, 2022 4.56 Mn
Mar 31, 2022 738,000.00
Dec 31, 2021 170,000.00
Sep 30, 2021 116.79 Mn
API Access

Viridian Therapeutics, Inc.\DE Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=VRDN&period=max&api_key=YOUR_API_KEY